Aprinoia therapeutics

Index
Globenewswire

APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 for the Diagnosis of Progressive Supranuclear Palsy

Globenewswire

APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer